Residency · Chapel Hill, NC
Sponsored by University of North Carolina Hospitals
Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.
Lancet (London, England) · 2024 · 149 citations · Christopher Sayed
Wastewater sequencing reveals early cryptic SARS-CoV-2 variant transmission.
Nature · 2022 · 359 citations · Ben Henson
A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring.
Dermatology and therapy · 2023 · 180 citations · Hannah Cornman
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations.
Journal of the American Academy of Dermatology · 2022 · 187 citations · Christopher Sayed
Chronic Pruritus: A Review.
JAMA · 2024 · 97 citations · Sarah Chisolm
Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.
Journal of the American Academy of Dermatology · 2024 · 82 citations · David Rubenstein
Roflumilast Cream, 0.15%, for Atopic Dermatitis in Adults and Children: INTEGUMENT-1 and INTEGUMENT-2 Randomized Clinical Trials.
JAMA dermatology · 2024 · 56 citations · Laura Ferris
Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
The British journal of dermatology · 2024 · 69 citations · Hannah Cornman